ADX-096
Complement-mediated diseases
Discovery/PreclinicalActive; Strategic options being evaluated.
Key Facts
Indication
Complement-mediated diseases
Phase
Discovery/Preclinical
Status
Active; Strategic options being evaluated.
Company
About Q32 Bio
Q32 Bio is focused on discovering and developing innovative therapies that restore immune homeostasis in severe autoimmune and inflammatory diseases. The company's most advanced program, bempikibart, has shown promising clinical activity and a favorable safety profile in a Phase 2a trial for alopecia areata. Led by an experienced team of industry veterans, Q32 Bio is advancing a pipeline centered on modulating both the adaptive (via IL-7/TSLP) and innate (via complement) immune systems, with strategic evaluation ongoing for its complement platform.
View full company profileTherapeutic Areas
Other Complement-mediated diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Pozelimab | Regeneron Pharmaceuticals | Phase 2/3 |
| ARGX-117 | Argenx | Phase 1/2 |
| ANX009 | Annexon | Preclinical |
| C3d mAb fusions | Q32 Bio | Discovery/Preclinical |
| Complement-targeting nanobodies | Q32 Bio | Discovery/Preclinical |
| RLYB116 | Rallybio | Phase 1 |